Cellular uptake, distribution, and stability of 10-23 deoxyribozymes

被引:130
作者
Dass, CR [1 ]
Saravolac, EG [1 ]
Li, Y [1 ]
Sun, LQ [1 ]
机构
[1] Johnson & Johnson Res Labs, Eveleigh 1430, Australia
来源
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 2002年 / 12卷 / 05期
关键词
D O I
10.1089/108729002761381276
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cellular uptake, intracellular distribution, and stability of 33-mer deoxyribozyme oligonucleotides (DNAzymes) were examined in several cell lines. PAGE analysis revealed that there was a weak association between the DNAzyme and DOTAP or Superfect transfection reagents at charge ratios that were minimally toxic to cultured cells. Cellular uptake was analyzed by cell fractionation of radiolabeled DNAzyme, by FACS, and by fluorescent microscopic analysis of FITC-labeled and TAMRA-labeled DNAzyme. Altering DNAzyme size and chemistry did not significantly affect uptake into cells. Inspection of paraformaldehyde-fixed cells by fluorescence microscopy revealed that DNAzyme was distributed primarily in punctate structures surrounding the nucleus and that substantial delivery to the nucleus was not observed up to 24 hours after initiation of transfection. Incubation in human serum or plasma demonstrated that a 3'-inversion modification greatly increased DNAzyme stability (t(1/2) approximate to 22 hours) in comparison to the unmodified form (t(1/2) approximate to 70 minute). The 3'-inversion-modified DNAzymes remained stable during cellular uptake, and catalytically active oligonucleotide could be extracted from the cells 24 hours posttransfection. In smooth muscle cell proliferation assay, the modified DNAzyme targeting the c-myc gene showed a much stronger inhibitory effect than did the unmodified version. The present study demonstrates that DNAzymes with a 3'-inversion are readily delivered into cultured cells and are functionally stable for several hours in serum and within cells.
引用
收藏
页码:289 / 299
页数:11
相关论文
共 34 条
[1]   Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene [J].
Alvarez-Salas, LM ;
Arpawong, TE ;
DiPaolo, JA .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (05) :441-450
[2]   Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function [J].
Basu, S ;
Sriram, B ;
Goila, R ;
Banerjea, AC .
ANTIVIRAL RESEARCH, 2000, 46 (02) :125-134
[3]   BINDING, UPTAKE, AND INTRACELLULAR TRAFFICKING OF PHOSPHOROTHIOATE-MODIFIED OLIGODEOXYNUCLEOTIDES [J].
BELTINGER, C ;
SARAGOVI, HU ;
SMITH, RM ;
LESAUTEUR, L ;
SHAH, N ;
DEDIONISIO, L ;
CHRISTENSEN, L ;
RAIBLE, A ;
JARETT, L ;
GEWIRTZ, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1814-1823
[4]  
BENIMETSKAYA L, 1999, METHOD ENZYMOL, V212, P287
[5]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[6]   Target site selection for an RNA-cleaving catalytic DNA [J].
Cairns, MJ ;
Hopkins, TM ;
Witherington, C ;
Wang, L ;
Sun, LQ .
NATURE BIOTECHNOLOGY, 1999, 17 (05) :480-486
[7]   Novel cationic amphiphiles as delivery agents for antisense oligonucleotides [J].
DeLong, RK ;
Yoo, H ;
Alahari, SK ;
Fisher, M ;
Short, SM ;
Kang, SH ;
Kole, R ;
Janout, V ;
Regan, SL ;
Juliano, RL .
NUCLEIC ACIDS RESEARCH, 1999, 27 (16) :3334-3341
[8]   Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleolides [J].
Dheur, S ;
Dias, N ;
Van Aerschot, A ;
Herdewijn, P ;
Bettinger, T ;
Rémy, JS ;
Hélène, C ;
Saison-Behmoaras, ET .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (06) :515-525
[9]   Inhibition of hepatitis B virus X gene expression by novel DNA enzymes [J].
Goila, R ;
Banerjea, AC .
BIOCHEMICAL JOURNAL, 2001, 353 :701-708
[10]   On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids [J].
Hafez, IM ;
Maurer, N ;
Cullis, PR .
GENE THERAPY, 2001, 8 (15) :1188-1196